Current Opinion in Infectious Diseases最新文献_第4页

Reassessment of the role of combination antifungal therapy in the current era. 重新评估抗真菌联合疗法在当今时代的作用。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-09-12 DOI: 10.1097/qco.0000000000001063

Chin Fen Neoh,Monica A Slavin

{"title":"Reassessment of the role of combination antifungal therapy in the current era.","authors":"Chin Fen Neoh,Monica A Slavin","doi":"10.1097/qco.0000000000001063","DOIUrl":"https://doi.org/10.1097/qco.0000000000001063","url":null,"abstract":"PURPOSE OF REVIEWGiven the high mortality and morbidity associated with invasive fungal diseases (IFDs), the use of combination antifungal therapies is often considered despite the dearth of data. This review aims to summarize the current state of literature of combination antifungal therapies, discussing the potential roles of newer antifungal combinations and key considerations for their clinical use.RECENT FINDINGSIn infections other than cryptococcal meningitis or in the setting of empirical treatment for suspected azole-resistant Aspergillus infections, the utility of the combination antifungal approaches remains controversial given the paucity of well designed randomized controlled trials. Data on potential combined antifungal treatments have been primarily limited to in-vitro studies, animal models, case reports and/or observational studies. With availability of novel antifungal agents (e.g. ibrexafungerp, fosmanogepix), combination therapy to treat mould infections should be re-visited. A phase 2 clinical trial of ibrexafungerp combined with voriconazole to treat invasive pulmonary aspergillosis is on-going.SUMMARYThere is a need to investigate the use of combination antifungal agents. This includes delineating the indication of these combined antifungal therapies and determining how to use them most appropriately in the clinical setting.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"5 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chains of misery: surging invasive group A streptococcal disease. 痛苦之链：侵袭性 A 组链球菌疾病激增。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-09-09 DOI: 10.1097/qco.0000000000001064

Kimberly Davis,Yara-Natalie Abo,Andrew C Steer,Joshua Osowicki

{"title":"Chains of misery: surging invasive group A streptococcal disease.","authors":"Kimberly Davis,Yara-Natalie Abo,Andrew C Steer,Joshua Osowicki","doi":"10.1097/qco.0000000000001064","DOIUrl":"https://doi.org/10.1097/qco.0000000000001064","url":null,"abstract":"PURPOSE OF REVIEWWe describe the epidemiology of the recent global surge in invasive group A streptococcal (GAS) disease and consider its proximate and distal causes. We highlight important knowledge gaps regarding clinical management and discuss potential strategies for prevention.RECENT FINDINGSRates of invasive GAS (iGAS) disease were increasing globally prior to the COVID-19 pandemic. Since mid-2022, following the worst years of the pandemic in 2020 and 2021, many countries with systems to monitor GAS syndromes have reported surges in cases of iGAS concurrent with increased scarlet fever, pharyngitis, and viral co-infections. The emergence of the hypervirulent M1UK strain as a cause of iGAS, particularly in high income countries, is concerning. New data are emerging on the transmission dynamics of GAS. GAS remains universally susceptible to penicillin but there are increasing reports of macrolide and lincosamide resistance, particularly in invasive isolates, with uncertain clinical consequences. Intravenous immunoglobulin is used widely for streptococcal toxic shock syndrome and necrotizing soft tissue infections, although there is limited clinical evidence, and none from a completed randomized controlled trial. Intensive and expensive efforts at population-level control of GAS infections and postinfectious autoimmune complications have been only partially successful. The great hope for control of GAS diseases remains vaccine development. However, all modern vaccine candidates remain in the early development stage.SUMMARYIn many countries, iGAS rates surged from mid-2022 in the aftermath of pandemic control measures and physical distancing. The emergence of a dominant hypervirulent strain is an important but incomplete explanation for this phenomenon. Clinical management of iGAS remains highly empirical and new data has not emerged. A vaccine remains the most likely means of achieving a sustainable reduction in the burden of iGAS.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"269 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update on diagnosis and treatment of fungal meningitis: lessons from recent outbreaks. 真菌性脑膜炎诊断和治疗的最新进展：从近期爆发的疫情中汲取教训。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-09-04 DOI: 10.1097/qco.0000000000001061

Paula Beltran-Reyes,Luis Ostrosky-Zeichner,Maria F Gonzalez-Lara

{"title":"Update on diagnosis and treatment of fungal meningitis: lessons from recent outbreaks.","authors":"Paula Beltran-Reyes,Luis Ostrosky-Zeichner,Maria F Gonzalez-Lara","doi":"10.1097/qco.0000000000001061","DOIUrl":"https://doi.org/10.1097/qco.0000000000001061","url":null,"abstract":"PURPOSE OF REVIEWRecently, fungal meningitis outbreaks have occurred in association with neuraxial and epidural anesthesia in immunocompetent patients. Herein, we describe the course of those outbreaks, their diagnosis, treatment, prognosis, and lessons learned.RECENT FINDINGSTwo outbreaks of Fusarium solani meningitis during 2022-2023 were associated with epidural anesthesia in two distant cities in Mexico (Durango and Matamoros). The initial etiological agent identification was delayed due to insensitivity of cultures. A Fusarium solani qPCR was validated and positive in 38% cerebrospinal fluid (CSF) samples from Durango, while BD-Glucan allowed early diagnosis of the index case in Matamoros. Antifungal treatment with voriconazole and liposomal amphotericin B (L-AmB) was recommended. Overall mortality was 51%. Once the cause was confirmed, some patients received fosmanogepix.SUMMARYFungal meningitis outbreaks due to filamentous fungi are usually associated with direct epidural inoculation. They result in severe presentations and high mortality. Early diagnosis should be suspected, BD-Glucan CSF testing screening is recommended. Aggressive antifungal treatment based on antifungal susceptibility testing should be administered as early as possible. The advent of molecular diagnostic methods and new antifungal drugs may allow for timely diagnosis and treatment, increasing the chances of survival.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"9 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inborn errors of immunity and invasive fungal infections: presentation and management. 先天性免疫错误与侵袭性真菌感染：表现与处理。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-09-04 DOI: 10.1097/qco.0000000000001062

Olivier Paccoud,Adilia Warris,Anne Puel,Fanny Lanternier

{"title":"Inborn errors of immunity and invasive fungal infections: presentation and management.","authors":"Olivier Paccoud,Adilia Warris,Anne Puel,Fanny Lanternier","doi":"10.1097/qco.0000000000001062","DOIUrl":"https://doi.org/10.1097/qco.0000000000001062","url":null,"abstract":"PURPOSE OF REVIEWWe review the clinical presentations of invasive fungal infections in a selection of inborn errors of immunity. In addition, we review the particularities of their management, including antifungal therapy, prophylaxis, and immunomodulatory treatments.RECENT FINDINGSPatients with chronic granulomatous disease and with signal transducer and activator of transcription 3 (STAT3) deficiency are particularly prone to aspergillosis. Mold-active antifungal prophylaxis should be prescribed to all patients with chronic granulomatous disease, and in patients with STAT3 deficiency and underlying parenchymal lung disease. Invasive fungal infections are rare in patients with STAT1 gain-of-function mutations, while the clinical phenotype of caspase-associated recruitment domain-containing protein 9 deficiency encompasses a wide range of superficial and invasive fungal infections. Most patients with inborn errors of immunity and invasive fungal infections require prolonged durations of antifungals. Hematopoietic stem cell transplantation should be considered early for patients with chronic granulomatous disease, but results have been more mixed for other inborn errors of immunity with active invasive fungal infections.SUMMARYInborn errors of immunity can confer increased susceptibility to a variety of invasive fungal infections, which can present with specific clinical and radiological features. Management of fungal infections in these patients is often challenging, and relies on a combination of antimicrobial prophylaxis, antifungal treatments, and immunomodulation.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"58 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolution of knowledge for treating Gram-negative bacterial infections. 治疗革兰氏阴性细菌感染的知识演变。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-27 DOI: 10.1097/qco.0000000000001055

Almudena Burillo,Emilio Bouza

{"title":"The evolution of knowledge for treating Gram-negative bacterial infections.","authors":"Almudena Burillo,Emilio Bouza","doi":"10.1097/qco.0000000000001055","DOIUrl":"https://doi.org/10.1097/qco.0000000000001055","url":null,"abstract":"PURPOSE OF REVIEWInfections caused by nonprimarily pathogenic Gram-negative bacilli (GNB) have been increasingly reported from the second half of the 20th century to the present. This phenomenon has expanded during the antibiotic era and in the presence of immunodeficiency.Before the discovery of sulphonamides and penicillin G, infections caused by GNB were rare compared to Gram-positive infections. The advent of anticancer therapy, the expansion of surgical procedures, the use of corticosteroids, and the implantation of prosthetic materials, along with better control of Gram-positive infections, have promoted the current increase in GNB infections.GNB have similar antimicrobial targets to Gram-positive bacteria. However, only antibiotics that can penetrate the double membrane of GNB and remain in them for a sufficient duration have antibacterial activity against them.RECENT FINDINGSSulphonamides and early penicillins had limited activity against GNB. Ampicillin and subsequent beta-lactams expanded their spectrum to treat GNB. Aminoglycosides may re-surge with less toxic drugs, as highly resistant to beta-lactams GNB rise. Polymyxins, tetracyclines, and fluoroquinolones are also used for GNB. Combinations with other agents may be needed in specific cases, such as in the central nervous system and prostate, where beta-lactams may have difficulty reaching the infection site.Alternatives to current treatments must be sought in the discovery of new drug families and therapies such as phage therapy combined with antibiotics.SUMMARYNarrower-spectrum immunosuppressive therapies and antibiotics, antimicrobials that minimally intervene with the human microbiota, and instant diagnostic methods are necessary to imagine a future where currently dominant bacteria in infectious pathology lose their preeminence.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"27 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections. 舒巴坦-杜鲁巴坦在治疗耐碳青霉烯类杆菌感染中的作用。

IF 3.9 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-14 DOI: 10.1097/qco.0000000000001059

Matteo Bassetti,Daniele Roberto Giacobbe,Nadia Castaldo,Antonio Vena

{"title":"The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.","authors":"Matteo Bassetti,Daniele Roberto Giacobbe,Nadia Castaldo,Antonio Vena","doi":"10.1097/qco.0000000000001059","DOIUrl":"https://doi.org/10.1097/qco.0000000000001059","url":null,"abstract":"PURPOSE OF REVIEWInfections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles. Sulbactam-durlobactam is a novel β-lactamase inhibitors combination specifically developed to target A. baumannii, including carbapenem-resistant strains. The purpose of this review is to assess the current evidence supporting the role of sulbactam-durlobactam in the management of A. baumannii infections.RECENT FINDINGSWe summarize the available evidence regarding the pharmacokinetic and pharmacodynamic profiles of sulbactam-durlobactam from key in-vitro and in-vivo studies. Additionally, efficacy results from the Phase III randomized controlled trial and real-world data on sulbactam-durlobactam's use against severe A. baumannii infections are also discussed.SUMMARYSulbactam-durlobactam is a promising addition to the treatment options for carbapenem-resistant A. baumannii infections. Ongoing research and vigilance are essential to monitor the development of in-vivo resistance, assess effectiveness across diverse patient populations, and explore potential synergistic combinations with other antimicrobials. Careful stewardship and comprehensive clinician education will be crucial to optimizing the clinical use of sulbactam-durlobactam.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":"13 1","pages":""},"PeriodicalIF":3.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142211885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NSAIDs for early management of acute respiratory infections. 非甾体抗炎药用于急性呼吸道感染的早期治疗。

IF 3.6 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-01 Epub Date: 2024-05-23 DOI: 10.1097/QCO.0000000000001024

Matteo Bassetti, Massimo Andreoni, Pierachille Santus, Francesco Scaglione

{"title":"NSAIDs for early management of acute respiratory infections.","authors":"Matteo Bassetti, Massimo Andreoni, Pierachille Santus, Francesco Scaglione","doi":"10.1097/QCO.0000000000001024","DOIUrl":"10.1097/QCO.0000000000001024","url":null,"abstract":"Purpose of review: To review the rationale for and the potential clinical benefits of an early approach to viral acute respiratory infections with NSAIDs to switch off the inflammatory cascade before the inflammatory process becomes complicated.Recent findings: It has been shown that in COVID-19 as in other viral respiratory infections proinflammatory cytokines are produced, which are responsible of respiratory and systemic symptoms. There have been concerns that NSAIDs could increase susceptibility to SARS-CoV-2 infection or aggravate COVID-19. However, recent articles reviewing experimental research, observational clinical studies, randomized clinical trials, and meta-analyses conclude that there is no basis to limit the use of NSAIDs, which may instead represent effective self-care measures to control symptoms.Summary: The inflammatory response plays a pivotal role in the early phase of acute respiratory tract infections (ARTIs); a correct diagnosis of the cause and a prompt therapeutic approach with NSAIDs may have the potential to control the pathophysiological mechanisms that can complicate the condition, while reducing symptoms to the benefit of the patient. A timely treatment with NSAIDs may limit the inappropriate use of other categories of drugs, such as antibiotics, which are useless when viral cause is confirmed and whose inappropriate use is responsible for the development of resistance.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"304-311"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11213495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141080775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human herpesvirus-6, HHV-8 and parvovirus B19 after allogeneic hematopoietic cell transplant: the lesser-known viral complications. 异体造血细胞移植后的人类疱疹病毒-6、HHV-8 和副病毒 B19：鲜为人知的病毒并发症。

IF 3.6 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-01 Epub Date: 2024-05-06 DOI: 10.1097/QCO.0000000000001020

Eleftheria Kampouri, Jessica S Little, Roberto Crocchiolo, Joshua A Hill

{"title":"Human herpesvirus-6, HHV-8 and parvovirus B19 after allogeneic hematopoietic cell transplant: the lesser-known viral complications.","authors":"Eleftheria Kampouri, Jessica S Little, Roberto Crocchiolo, Joshua A Hill","doi":"10.1097/QCO.0000000000001020","DOIUrl":"10.1097/QCO.0000000000001020","url":null,"abstract":"Purpose of review: Viral infections continue to burden allogeneic hematopoietic cell transplant (HCT) recipients. We review the epidemiology, diagnosis, and management of human herpesvirus (HHV)-6, HHV-8 and parvovirus B19 following HCT.Recent findings: Advances in HCT practices significantly improved outcomes but impact viral epidemiology: post-transplant cyclophosphamide for graft-versus-host disease prevention increases HHV-6 reactivation risk while the impact of letermovir for CMV prophylaxis - and resulting decrease in broad-spectrum antivirals - is more complex. Beyond the well established HHV-6 encephalitis, recent evidence implicates HHV-6 in pneumonitis. Novel less toxic therapeutic approaches (brincidofovir, virus-specific T-cells) may enable preventive strategies in the future. HHV-8 is the causal agent of Kaposi's sarcoma, which is only sporadically reported after HCT, but other manifestations are possible and not well elucidated. Parvovirus B19 can cause severe disease post-HCT, frequently manifesting with anemia, but can also be easily overlooked due to lack of routine screening and ambiguity of manifestations.Summary: Studies should establish the contemporary epidemiology of HHV-6, and other more insidious viruses, such as HHV-8 and parvovirus B19 following HCT and should encompass novel cellular therapies. Standardized and readily available diagnostic methods are key to elucidate epidemiology and optimize preventive and therapeutic strategies to mitigate the burden of infection.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"245-253"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Horizontal versus vertical strategies for infection prevention: current practices and controversies. 预防感染的横向与纵向策略：当前做法与争议。

IF 3.6 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-01 Epub Date: 2024-05-31 DOI: 10.1097/QCO.0000000000001027

Salma Abbas, Michael P Stevens

{"title":"Horizontal versus vertical strategies for infection prevention: current practices and controversies.","authors":"Salma Abbas, Michael P Stevens","doi":"10.1097/QCO.0000000000001027","DOIUrl":"10.1097/QCO.0000000000001027","url":null,"abstract":"Purpose of review: Healthcare-associated infections (HAIs) represent a major burden on healthcare facilities. Effective infection prevention strategies are essential to prevent the spread of HAIs. These can be broadly classified as vertical and horizontal interventions. Through this review, we aim to assess the merits of these strategies.Recent findings: Vertical strategies include active surveillance testing and isolation for patients infected or colonized with a particular organism. These strategies are beneficial to curb the spread of emerging pathogens and during outbreaks. However, the routine use of contact precautions for organisms such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus remains controversial. Horizontal interventions are larger-scale and reduce HAIs by targeting a common mode of transmission shared by multiple organisms. Among these, hand hygiene, chlorhexidine gluconate bathing of select patients and environmental decontamination are the most high-yield and must be incorporated into infection prevention programs. As antimicrobial stewardship is also an effective horizontal strategy, antimicrobial stewardship programs must operate in synergy with infection prevention programs for maximal impact.Summary: Overall, horizontal interventions are considered more cost-effective and have a broader impact. Infection control programs may opt for a combination of vertical and horizontal strategies based on local epidemiology and available resources.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"282-289"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV. 艾滋病毒感染者的造血干细胞移植和细胞疗法。

IF 3.6 3区医学

Current Opinion in Infectious Diseases Pub Date : 2024-08-01 Epub Date: 2024-05-31 DOI: 10.1097/QCO.0000000000001022

Paul G Rubinstein, Carlos Galvez, Richard F Ambinder

{"title":"Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV.","authors":"Paul G Rubinstein, Carlos Galvez, Richard F Ambinder","doi":"10.1097/QCO.0000000000001022","DOIUrl":"10.1097/QCO.0000000000001022","url":null,"abstract":"Purpose of review: Summarize the latest research of both stem cell transplantation and cellular therapy and present the implications with respect to persons with HIV (PWH), hematologic malignancies, and HIV-1 cure.Recent findings: Allogeneic (alloSCT) and autologous (autoSCT) stem cell transplantation have been shown to be well tolerated and effective regardless of HIV-1 status. AlloSCT leads to a decrease in the HIV-1 latently infected reservoir orders of magnitude below that achieved with antiretroviral therapy (ART) alone. Utilization of CCR5Δ2/Δ32 donors in an alloSCT has resulted in HIV-1 cures. In the last 12 months, three cases of cure have been published, giving further insight into the conditions required for HIV-1 control. Other advances in the treatment of hematological cancers include chimeric antigen receptor T-cell (CART) therapy, which are active in PWH with lymphoma.Summary: Here we discuss the advances in SCT and cellular therapy in PWH and cancer. Additionally, we discuss how these technologies are being utilized to achieve HIV-1 cure.","PeriodicalId":10880,"journal":{"name":"Current Opinion in Infectious Diseases","volume":" ","pages":"254-263"},"PeriodicalIF":3.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141184086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0